Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.36
Schlusskurs vom Vortag:
$0.36
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
$1.40M
Nettoeinkommen (Verlust:
$-1.78M
KGV:
0.00
EPS:
-0.543
Netto-Cashflow:
$-1.09M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-96.88%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$0.735
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Firmenname
Avenue Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare ATXI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.00 | 0 | 1.40M | -1.78M | -1.09M | -0.543 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten
Enterprise value to EBITDA forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to sales forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to book forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to sales forward of Avenue Therapeutics, Inc. – LSX:A40BWJ - TradingView
Enterprise value to EBIT forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to earnings forward of Avenue Therapeutics, Inc. – LSX:A40BWJ - TradingView
Avenue Therapeutics, Inc. Actuals & Estimates (OTC:ATXI) - TradingView
Avenue Therapeutics (ATXI) Q1 2026 earnings summary - Quartr
Avenue Therapeutics (ATXI) Q3 2024 earnings summary - Quartr
Avenue Therapeutics (ATXI) AGM 2024 Summary - Quartr
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering - Business Wire
Definium Therapeutics, Inc. Announces Proposed Public Offering - BioSpace
Fortress Biotech StockSaturday deep dive on the business model - AD HOC NEWS
Madison Avenue Partners LP Reduces Stock Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - StreetInsider
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds - StreetInsider
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - StreetInsider
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - TradingView
Summit Therapeutics Announces Proposed Public Offering of Common Stock - FinancialContent
Tango Therapeutics Announces Proposed $500 Million Public Offering - The Manila Times
Neuro stocks outpace broader markets as psychedelics, Axsome shine - BioWorld News
Chiesi (KALV) offers $27.00/share; HSR, German and Italian clearances noted - Stock Titan
Madison Avenue entities (INDV) disclose 4.32M-share, ~3.5% stake - Stock Titan
Priority review voucher sale drives Fortress Biotech (FBIO) Q1 2026 profit and cash surge - Stock Titan
Jeremy Levin reports 4.5% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
Click Therapeutics Positions Over-the-Counter Digital Therapeutics as New Growth Avenue - TipRanks
State Street (VNDA) discloses 3.02M shares, 5.1% ownership on 13G - Stock Titan
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - PharmiWeb.com
Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Hold at Wall Street Zen - MarketBeat
MSN Money - MSN
Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN
AVENUE THERAPEUTICS, INC. 1Q 2026: Net loss $0.7M, Revenue $0— 10-Q Summary - TradingView
Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Avenue Therapeutics (OTC: ATXI) cuts Q1 loss but warns on going concern - Stock Titan
Avenue Therapeutics | 10-Q: Quarterly report - Moomoo
Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering - BioSpace
Board elections and auditor vote at MiNK Therapeutics (NASDAQ: INKT) - Stock Titan
Executive pay, major holders and votes in Foghorn (NASDAQ: FHTX) 2026 proxy - Stock Titan
Executive pay and audits headline Monte Rosa (NASDAQ: GLUE) 2026 proxy - Stock Titan
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering - The Manila Times
Akebia (NASDAQ: AKBA) plans major increase in authorized common shares - Stock Titan
Abeona Therapeutics (NASDAQ: ABEO) sets 2026 virtual meeting on directors, pay and equity plan - Stock Titan
Intellia Therapeutics Announces Proposed Public Offering of Common Stock - Intellia Therapeutics
Form S-1/A Hemab Therapeutics Holdi - StreetInsider
Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang - Seeking Alpha
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
Coya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Tango Therapeutics (NASDAQ: TNGX) details 2026 virtual meeting, director elections and pay vote - Stock Titan
Kailera Therapeutics Announces Pricing of Initial Public Offering - GlobeNewswire
Does Relmada Therapeutics (RLMD) have the potential to rally 75.58% as Wall Street analysts expect? - MSN
Visa Inc. $V is Douglas Lane & Associates LLC’s 10th Largest Position - Defense World
Finanzdaten der Avenue Therapeutics Inc-Aktie (ATXI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
Kapitalisierung:
|
Volumen (24h):